Valuation: HighTide Therapeutics, Inc.

Capitalization 1.51B 1.74B 222M 191M 175M 167M 306M 21.34B 311M 2.1B 811M 10.12B 835M 817M 35.31B P/E ratio 2023
-3.25x
P/E ratio 2024 -1.41x
Enterprise value 1.1B 1.27B 162M 139M 127M 121M 222M 15.53B 226M 1.53B 590M 7.36B 607M 594M 25.68B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
44.17%
Yield 2023 *
-
Yield 2024 -
1 day-2.31%
1 week-8.41%
Current month-0.78%
1 month+6.42%
3 months+46.54%
6 months+27.42%
Current year+29.15%
1 week 3.8
Extreme 3.8
4.17
1 month 3.47
Extreme 3.47
4.72
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 57 2010-12-31
Director of Finance/CFO 57 2022-11-30
Chief Tech/Sci/R&D Officer - 2026-02-01
Director TitleAgeSince
Chairman 57 -
Director/Board Member 44 2023-05-14
Director/Board Member 68 2020-11-29
Change 5d. change 1-year change 3-years change Capi.($)
-2.31%-8.41%+16.51% - 284M
-0.14%+3.28%+45.23%+87.25% 50.39B
+0.12%-7.32%+68.98%+55.74% 46.03B
-5.60%+3.94%+66.35%+482.70% 25.06B
-2.65%-3.73%-2.75%-14.91% 23.26B
+3.19%+1.20%+41.51%-26.86% 17.24B
-1.66%-4.24%+29.99%-41.30% 16.15B
-2.91%-12.84%+46.76%+182.49% 14.56B
-7.00%-1.63%-25.85%+880.81% 14.08B
+0.41%-4.04%+39.40% - 12.94B
Average -1.86%-1.46%+32.61%+200.74% 22B
Weighted average by Cap. -1.42%-0.34%+41.29%+157.85%

Financials

2023 2024
Net sales - -
Net income -939M -1.08B -138M -119M -108M -103M -190M -13.24B -193M -1.3B -503M -6.28B -518M -507M -21.9B -382M -439M -56.07M -48.21M -44.08M -42.06M -77.03M -5.38B -78.44M -530M -205M -2.55B -210M -206M -8.9B
Net Debt -720M -828M -106M -90.92M -83.11M -79.32M -145M -10.15B -148M -999M -386M -4.81B -397M -388M -16.78B -413M -475M -60.62M -52.13M -47.65M -45.48M -83.29M -5.82B -84.81M -573M -221M -2.76B -227M -223M -9.62B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
51
Date Price Change Volume
26-05-15 3.810 $ -2.31% 205,000
26-05-14 3.900 $ 0.00% 238,000
26-05-13 3.900 $ -2.50% 320,500
26-05-12 4.000 $ -1.48% 408,000
26-05-11 4.060 $ -1.93% 552,500

Annual profits - Rate of surprise